Madrigal Pharmaceuticals Inc  

(Public, NASDAQ:MDGL)   Watch this stock  
Find more results for MDGL
135.53
+1.68 (1.26%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 131.71 - 137.54
52 week 13.09 - 154.75
Open 134.31
Vol / Avg. 117,720.00/232,101.00
Mkt cap 1.92B
P/E     -
Div/yield     -
EPS -2.46
Shares 14.23M
Beta 1.19
Inst. own 76%
Feb 8, 2018
Madrigal Pharmaceuticals Inc Phase 2 Results for Madrigal's MGL-3196 in heterozygous familial hypercholesterolemia Call - Webcast
Dec 6, 2017
Madrigal Pharmaceuticals, Inc. - Special Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -51.25% -126.94%
Return on average equity -57.86% -
Employees 8 -
CDP Score - -

Address

200 Barr Harbor Dr Ste 400
CONSHOHOCKEN, PA 19428-2978
United States - Map
+1-404-3809263 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Officers and directors

Paul A. Friedman M.D. Chairman of the Board, Chief Executive Officer
Age: 74
Bio & Compensation  - Reuters
Rebecca A. Taub M.D. Founder, Chief Medical Officer, Executive Vice President, Research & Development and Director
Age: 65
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Frederick B. Craves Ph.D. Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 66
Bio & Compensation  - Reuters
Keith R. Gollust Independent Director
Age: 71
Bio & Compensation  - Reuters
Richard S. Levy M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
David V. Milligan Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters